Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Feb 2008

Vergani Barbara, Cicero Mirko Lo, Vigano' Ottavia, Sirianni Francesca, Ferramosca Stefania, Vitiello Paola, Di Vincenzo Paola, Pia De Pasquale Maria, Galli Massimo, Rusconi Stefano

Abstract excerpt

BACKGROUND: Previous in vitro studies indicated that Atazanavir (ATV) has a distinct resistance profile than other protease inhibitors (PIs). In treatment-experienced patients ATV resistance is characterised by the accumulation of at least four mutations among those that confer cross-resistance to the PIs. OBJECTIVE: We studied the evolution of PIs resistance mutations in 10 HAART-failed patients undergoing ATV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Oligopeptides

Share to Pyridines

Source

Identifiers

PMID: 18024202
DOI: 10.1016/j.jcv.2007.10.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.PMID 18024202Read ↗

Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.Semantic proximity Read ↗

Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.Semantic proximity Read ↗

Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance MutationsSemantic proximity Read ↗

Cross-resistance patterns among HIV protease inhibitors.Semantic proximity Read ↗

Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.Semantic proximity Read ↗

[Viral resistance and genetic barrier of atazanavir].Semantic proximity Read ↗

Analysis of the protease sequences of HIV-1 infected individuals after Indinavir monotherapy.Semantic proximity Read ↗

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.Semantic proximity Read ↗

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors.Semantic proximity Read ↗

Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.Semantic proximity Read ↗

Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.Semantic proximity Read ↗

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.